公开(公告)号：US09962384B1

公开(公告)日：2018-05-08

申请号：US15697728

申请日：2017-09-07

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Yun Kyung Kim ,  Sung Su Lim ,  Do Hee Kim ,  Md. Mamunul Haque ,  Seul Gi Shin ,  Ha Eun Lee ,  Tae Hun Kim ,  Sang Min Lim ,  Ae Nim Pae

IPC: A61K31/50 ,  A61K47/36 ,  C07D237/10

CPC classification number: A61K31/50 ,  A61K47/36 ,  C07D237/04 ,  C07D237/10

Abstract: Disclosed is a levosimendan compound, an optically active isomer thereof, or a pharmaceutically acceptable salt thereof, which is used for the prevention and/or treatment of diseases caused by tau aggregation or phosphorylation, such as neurodegenerative diseases (e.g., Alzheimer disease). In accordance with yet another aspect of the present invention, there is provided a health functional food for preventing or treating tau aggregation-related diseases, containing a levosimendan compound or a pharmaceutically acceptable salt, stereoisomer or solvate thereof.

公开(公告)号：US09493423B2

公开(公告)日：2016-11-15

申请号：US14632839

申请日：2015-02-26

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ghil Soo Nam ,  Kyung Il Choi ,  Jung Hyun Kim ,  Ae Nim Pae ,  Jin Ri Hong ,  Jae Kyun Lee

IPC: C07D231/12 ,  C07D417/14 ,  C07D401/12 ,  C07D417/06

CPC classification number: C07D231/12 ,  C07D401/12 ,  C07D417/06 ,  C07D417/14

Abstract: Disclosed herein are an N-(pyrazolylmethyl)arylsulfonamide derivative useful as a calcium ion channel blocker, a pharmaceutically acceptable salt thereof, and the medicinal use thereof as a therapeutic agent using its calcium ion channel blocking effect.

Abstract translation: 本文公开了可用作钙离子通道阻断剂的N-（吡唑基甲基）芳基磺酰胺衍生物及其药学上可接受的盐，其药物用途为其钙离子通道阻断作用的治疗剂。

公开(公告)号：US10544427B2

公开(公告)日：2020-01-28

申请号：US15709822

申请日：2017-09-20

Applicant: Korea Institute of Science and Technology

Inventor： Do Hee Kim ,  Seul Gi Shin ,  Sung Su Lim ,  Ae Nim Pae ,  Dong Jin Kim ,  Yun Kyung Kim

IPC: A01K67/027 ,  C12N15/85 ,  C07K14/47 ,  G01N33/50 ,  G01N33/68

Abstract: Disclosed is a vector pair for screening tau oligomer formation, a mouse embryo introduced with the vector pair, a transgenic model mouse of neurological disease, obtained from the mouse embryo, and a method of screening a tau oligomer formation inhibitor candidate using the transgenic model mouse. More specifically, the present invention provides vector pair for screening tau oligomer formation, comprising: a first vector comprising a first tau gene, a first fluorescence protein gene and a first neuron-specific promoter; and a second vector comprising a second tau gene, a second fluorescence protein gene and a second neuron-specific promoter, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first tau gene and a protein expressed from the second tau gene.

公开(公告)号：US10421779B2

公开(公告)日：2019-09-24

申请号：US15687203

申请日：2017-08-25

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  POSTECH ACADEMY-INDUSTRY FOUNDATION

Inventor： Gyo Chang Keum ,  Eunice Eun Kyeong Kim ,  Sung Key Jang ,  Hee Sun Kim ,  Ae Nim Pae ,  Hua Li ,  Jin Hyeong Park ,  Jin Sook Kwak

IPC: C07D209/88 ,  C07K5/065 ,  C07K5/062 ,  A61K38/00

Abstract: The present invention relates to a carbazole compound having anti-virus activity, and more particularly, to a novel compound selected from the group of consisting of a carbazole compound which shows excellent anti-proliferative efficacy against hepatitis C virus (HCV), a pharmaceutically acceptable salt thereof, a hydrate thereof, and an isomer thereof; an anti-virus pharmaceutical composition including the novel compound as an active ingredient; a pharmaceutical composition for preventing or treating liver diseases caused by hepatitis C virus; and a method of preparing the novel compound.

公开(公告)号：US20180119169A1

公开(公告)日：2018-05-03

申请号：US15709822

申请日：2017-09-20

Applicant: Korea Institute of Science and Technology

Inventor： Do Hee KIM ,  Seul Gi Shin ,  Sung Su Lim ,  Ae Nim Pae ,  Dong Jin Kim ,  Yun Kyung Kim

IPC: C12N15/85 ,  A01K67/027 ,  G01N33/50 ,  C07K14/47 ,  G01N33/68

CPC classification number: C12N15/8509 ,  A01K67/0275 ,  A01K2207/15 ,  A01K2217/05 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0312 ,  A01K2267/0318 ,  C07K14/47 ,  C07K2319/60 ,  C12N2015/8527 ,  C12N2015/8536 ,  C12N2015/859 ,  C12N2830/008 ,  G01N33/5058 ,  G01N33/5088 ,  G01N33/6896 ,  G01N2800/2814

Abstract: Disclosed is a vector pair for screening tau oligomer formation, a mouse embryo introduced with the vector pair, a transgenic model mouse of neurological disease, obtained from the mouse embryo, and a method of screening a tau oligomer formation inhibitor candidate using the transgenic model mouse. More specifically, the present invention provides vector pair for screening tau oligomer formation, comprising: a first vector comprising a first tau gene, a first fluorescence protein gene and a first neuron-specific promoter; and a second vector comprising a second tau gene, a second fluorescence protein gene and a second neuron-specific promoter, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first tau gene and a protein expressed from the second tau gene.

公开(公告)号：US08895602B1

公开(公告)日：2014-11-25

申请号：US14013487

申请日：2013-08-29

Applicant: Korea Institute of Science and Technology

Inventor： Ghil Soo Nam ,  Kyung Il Choi ,  Ae Nim Pae ,  Seon Hee Seo ,  Hyun Ah Choo ,  Gyo Chang Keum ,  Jung Hyun Kim

IPC: A61K31/4155 ,  C07D403/12

CPC classification number: C07D403/12 ,  A61K31/4155

Abstract: The present invention relates to a 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane derivatives useful as calcium channel blockers, pharmaceutically acceptable salts thereof and medical use of the calcium channel inhibiting effect of the compounds for treatment of diseases.

Abstract translation: 本发明涉及可用作钙通道阻滞剂的6-吡唑基氨基-3-取代的氮杂双环[3.1.0]己烷衍生物，其药学上可接受的盐，以及该化合物治疗疾病的钙通道抑制作用的医学应用。

公开(公告)号：US08946431B2

公开(公告)日：2015-02-03

申请号：US13943019

申请日：2013-07-16

Applicant: Korea Institute of Science and Technology

Inventor： Sun Joon Min ,  Yong Seo Cho ,  Ae Nim Pae ,  Eun Jeong Lim ,  Ji Yeong Kim ,  Myung Hee Son ,  Jae Kyun Lee

IPC: C07D215/06 ,  A61K31/04 ,  C07D215/20 ,  C07D401/06

CPC classification number: C07D215/06 ,  C07D215/20 ,  C07D401/06

Abstract: Provided is a 2-(substituted ethynyl)quinoline derivative having an mGluR5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mGluR5 receptor-mediated diseases such as Alzheimer's disease, senile dementia, Parkinson's disease, L-DOPA-induced dyskinesia, Huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile X syndrome, autism, migraine and gastroesophageal reflux disease (GERD).

Abstract translation: 本发明提供具有mGluR5拮抗活性的2-（取代乙炔基）喹啉衍生物及其药学上可接受的盐。 本发明的化合物可用作治疗和预防mGluR5受体介导的疾病如阿尔茨海默氏病，老年性痴呆，帕金森病，L-DOPA诱导的运动障碍，亨廷顿舞蹈病，肌萎缩性侧索硬化，多发性硬化，精神分裂症 ，焦虑症，抑郁症，神经性疼痛，药物依赖，脆性X综合征，自闭症，偏头痛和胃食管反流病（GERD）。